Skip to main content

Novel Rx

    RT @bella_mehta: Amazing lecture by Dr Jane Salmon for the RRF memorial foundation to honor Dr Shaun Ruddy #ACR20 @HSpec
    3 years 4 months ago
    Amazing lecture by Dr Jane Salmon for the RRF memorial foundation to honor Dr Shaun Ruddy #ACR20 @HSpecialSurgery @RheumNow the IMPACT study - pregnancy in APS with Certolizumab Therapy https://t.co/A9U11qI7zG
    RT @ejdein1: #ACR20 Abs#L11. Efficacy of TOFA vs PBO in AS. At week 16, %ASAS20 responders 56% v 29% PBO; %ASAS40 40% vs
    3 years 4 months ago
    #ACR20 Abs#L11. Efficacy of TOFA vs PBO in AS. At week 16, %ASAS20 responders 56% v 29% PBO; %ASAS40 40% vs 12%. @RheumNow #ACRBest https://t.co/3Faj64rBjd
    RT @drdavidliew: Following RITAZAREM, would you use rituximab maintenance for ANCA-associated vasculitis patients (cost
    3 years 4 months ago
    Following RITAZAREM, would you use rituximab maintenance for ANCA-associated vasculitis patients (cost aside)? @RheumNow
    RT @doctorRBC: Improvement of enthesitis US scores consistent with bDMARD initiation/change
    1⃣MASEI and OMERACT scores
    3 years 4 months ago
    Improvement of enthesitis US scores consistent with bDMARD initiation/change 1⃣MASEI and OMERACT scores improved at 3 mo/6mo 2⃣Associated with clinical activity outcomes @RheumNow #ACR20 Abs#1552 https://t.co/qnSEBaXrJo
    RT @drdavidliew: RITZAREM
    (RTX vs AZA maintenance post RTX induction relapsing AAV)
    what happened post-study?

    After #AC
    3 years 4 months ago
    RITZAREM (RTX vs AZA maintenance post RTX induction relapsing AAV) what happened post-study? After #ACR19, hope RTX confers ongoing benefit Answer: no. Same decline Is 1g q4m dosing not justified? Does that mean RTX needs to be continued, and in whom? #ACR20 ABST2052 @RheumNow https://t.co/tldGqca8xC
    RT @DrMiniDey: RITAZAREM trial long-term follow-up
    -RTX vs AZA after RTX-induced remission in ANCA #vasculitis
    -RTX supe
    3 years 4 months ago
    RITAZAREM trial long-term follow-up -RTX vs AZA after RTX-induced remission in ANCA #vasculitis -RTX superior to AZA to prevent relapse -Relapse common regardless of therapy; high-dose RTX not effective beyond treatment period Abs#2052 #ACR20 @RheumNow https://t.co/bW7IaMnVCG
    RT @drtinamahajan: Fantastic session about the 2020 guidelines for management of RA! Soon to be published.

    One major di
    3 years 4 months ago
    Fantastic session about the 2020 guidelines for management of RA! Soon to be published. One major difference from 2015 guidelines ➡️ Conditional recommendation to choose a Biologic over Triple Therapy in MTX-inadequate responders (Discussion about patient preference is key!) https://t.co/s016piIN7Q
    RT @DrMiniDey: SLR comparing the 4-dose ANCA #vasculitis (AAV) rituximab regimen (widely used in RCTs) to 2-dose #rheuma
    3 years 4 months ago
    SLR comparing the 4-dose ANCA #vasculitis (AAV) rituximab regimen (widely used in RCTs) to 2-dose #rheumatoidarthritis RTX regimen (common in clinical practice), to induce AAV remission, finds no difference in efficacy or safety. Abs#2048 #ACR20 @RheumNow https://t.co/WBaWN9d8vs
    RT @doctorRBC: Upadacitinib vs. Adalimumab vs. PBO in PsAPhase 3 RCT⬇️MSK symptoms, PsO, function, pain, fatigue,
    3 years 4 months ago

    Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu